Stocktoria
VERTEX PHARMACEUTICALS INC / MA VRTX
VERTEX PHARMACEUTICALS INC / MA (VRTX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $12.0B at a 32.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-05 | Truist Securities | Buy (main) |
| 2026-08-05 | Barclays | Overweight (main) |
| 2026-08-04 | TD Cowen | Buy (main) |
| 2026-08-04 | Cantor Fitzgerald | Overweight (main) |
| 2026-08-04 | Canaccord Genuity | Hold (main) |
| 2026-07-13 | UBS | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.286 |
| Retained earnings / assets | 0.529 |
| EBIT / assets | 0.163 |
| Equity / liabilities | 2.675 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/9 | 9.21 | 14.7 | +1% |
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 7/9 | -0.41 | 84.8 | +4.3% |
| OGN | Organon & Co. | 5/9 | — | 19 | -2.9% |
About VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
FAQ
Is VRTX financially healthy?
VERTEX PHARMACEUTICALS INC / MA's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does VRTX pay a dividend?
No, VERTEX PHARMACEUTICALS INC / MA does not currently pay a dividend.
How profitable is VRTX?
In FY2025, VERTEX PHARMACEUTICALS INC / MA had a net margin of 32.9% and a return on equity of 21.2%.
Is VRTX overvalued or undervalued?
VERTEX PHARMACEUTICALS INC / MA trades at about 34.3× trailing earnings — above its 10-year norm (10-year range 22.3×–263.9×, median 30.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for VRTX?
The average Wall-Street price target for VERTEX PHARMACEUTICALS INC / MA is $563.12, about 7.1% above the recent price, from 25 analysts (consensus: buy).
Is VRTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VERTEX PHARMACEUTICALS INC / MA: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 29.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.